Hemoglobin camel source nano antibody as well as preparation method and application thereof

By immunizing Bactrian camels and screening hemoglobin-specific antibody sequences, hemoglobin camel nano-antibody was prepared, which solved the error and cost problems of traditional hemoglobin detection methods, and achieved high sensitivity and high specificity hemoglobin detection, suitable for clinical practice. Diagnostic and biomedical research.

CN118994385AActive Publication Date: 2024-11-22XIAMEN BOSON BIOTECH CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411279402.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-22
Estimated Expiration
2044-09-12

AI Technical Summary

Technical Problem

The traditional hemoglobin concentration determination method has complicated sample processing, is susceptible to hemoglobin family proteins, many interference factors, high maintenance costs, and long experimental cycles, resulting in missed detection or misjudgment, and the detection antibody produces a non-specific cross-reaction with the sample of the same species, resulting in error.

Method used

Develop a hemoglobin camel nano-antibody and its preparation method. After four immunizations of the Bacteria, the lymphocyte RNA was extracted, the phage antibody library was constructed, and the hemoglobin-specific VHH-12 sequence was screened out, and the hemoglobin was obtained through recombinant expression. Camel nano-antibody, used to build detection kits, improve detection sensitivity and specificity.

Benefits of technology

It realizes high sensitivity and high specific hemoglobin detection, avoids non-specific recognition errors, reduces production costs, and improves the accuracy and reliability of test results. It is suitable for structural research, disease detection and drug development of hemoglobin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994385A_ABST
    Figure CN118994385A_ABST
Patent Text Reader

Abstract

The invention discloses a hemoglobin camel source nano antibody as well as a preparation method and application thereof, the hemoglobin camel source nano antibody is an amino acid sequence as shown in SEQ ID NO: 7, and the hemoglobin camel source nano antibody is derived from a bactrian camel and aims at hemoglobin specificity. The probe is small in molecule, easy to penetrate, high in specificity, good in stability, easy to produce and modify, wide in application prospect and capable of being applied to the fields of biomedical research, clinical diagnosis, treatment and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a hemoglobin nanobody and a preparation method and application thereof. Background Art

[0002] Hemoglobin (Hb) is a vital component of red blood cells. It is an iron-containing oxygen-transporting metalloprotein that plays an important role in the metabolic process of organisms and the innate immune system. The Hb content is a key physiological indicator for assessing whether a person has anemia or other blood diseases, and it is also one of the important criteria for measuring the health status of a person. At present, the methods for determining hemoglobin concentration mainly include: electrophoresis, liquid chromatography, spectrophotometry, electrochemical method, spectrophotometry and immunoassay. However, traditional methods are not conducive to census and rapid diagnosis because of cumbersome sample processing, susceptibility to the influence of hemoglobin family proteins, many interference factors, high maintenance costs, and long experimental cycles, which may lead to missed detection or misjudgment, and certain errors.

[0003] As a highly specific biorecognition molecule, anti-human hemoglobin antibodies ensure that the antibodies can distinguish and bind only to human hemoglobin, and do not cross-react with proteins with similar structures but different sources or functions. This specificity effectively avoids the deviation of test results that may be caused by non-specific binding, such as false negatives and false positives. During the detection process, it shows extremely high stability and can resist the influence of various potential interference factors, including non-specific proteins, lipids, sugars and other small molecule compounds, as well as possible changes in chemical or physical treatment conditions. This anti-interference ability ensures the accuracy and reliability of the test results, which is crucial for clinical diagnosis and the formulation of treatment plans.

[0004] Among them, nanobodies have the same antigen binding ability and structural stability as conventional monoclonal antibodies due to their extremely small protein molecule size. Compared with traditional antibodies, nanobodies have the advantages of strong antigen binding ability, high stability, low production cost, easy production, low immunogenicity, and unique biodistribution and pharmacokinetic properties, and have broad prospects in biomedical research and clinical applications. They have shown their potential as biosensors in many fields such as medicine, environment and food analysis, bringing revolutionary changes to disease diagnosis, treatment and basic scientific research.

[0005] In actual applications, if the detection antibody and the sample are derived from the same species, cross-reactions may easily occur between the detection antibody and the endogenous immunoglobulins in the sample, resulting in non-specific recognition, that is, light chain and heavy chain interference, leading to misjudgment. Summary of the invention

[0006] The purpose of the present invention is to provide a camel-derived hemoglobin nanoantibody with high sensitivity and strong specificity and a preparation method thereof. The camel-derived hemoglobin nanoantibody expands the user's antibody selection range in practical applications, such as for studying the structure and function of hemoglobin, building disease models, blood disease detection, blood transfusion compatibility detection, immunotherapy, and drug development and delivery, so as to avoid errors caused by nonspecific recognition of antibodies derived from the same species during practical applications.

[0007] To achieve the above objectives, the present invention proposes a hemoglobin camel-derived nanobody, the amino acid sequence of the hemoglobin camel-derived nanobody is shown in SEQ ID NO:7.

[0008] The present invention provides a nucleic acid molecule, which is used to encode the above-mentioned hemoglobin camel-derived nanobody, and the nucleic acid molecule is the nucleic acid sequence shown in SEQ ID NO:6.

[0009] The present invention provides a method for preparing a camel-derived hemoglobin nanobody, which is used to prepare the camel-derived hemoglobin nanobody, comprising:

[0010] S1. Separating hemoglobin antigen from human blood cells to prepare a hemoglobin solution;

[0011] S2, immunizing Bactrian camels four times with hemoglobin solution, with booster immunizations performed at intervals of 20, 60, and 40 days after the initial immunization;

[0012] S3. 15 days after the four immunizations, immune lymphocytes were obtained, and the total RNA of the lymphocytes was extracted to construct a cDNA library, and the cDNA library was then used as a template for specific amplification to obtain nanobody nucleic acid sequences, and the nanobody nucleic acid sequences were used to construct a phage antibody library;

[0013] S4, screening the VHH-12 sequence with hemoglobin specificity through the phage antibody library in step S3;

[0014] S5. Recombinantly express the VHH-12 sequence in step S4 to obtain the hemoglobin camel-derived nanobody.

[0015] The present invention provides a phage antibody library obtained by the above preparation method, and the phage antibody library includes the above SEQ ID NO:6 nucleic acid sequence.

[0016] The present invention provides a detection kit, comprising the above-mentioned camel-derived hemoglobin nanobody or the camel-derived hemoglobin nanobody obtained by the above-mentioned preparation method.

[0017] The present invention discloses a hemoglobin-specific camel-derived nanoantibody derived from Bactrian camels, which has small molecules, easy penetration, strong specificity, good stability, and is easy to produce and transform. It can be used in biomedical research, clinical diagnosis and treatment, and has broad application prospects. At the same time, antibodies from different species increase the specificity of the experiment and provide customers with more diverse antibody choices.

[0018] The preparation method of the present invention uses hemoglobin as an antigen to immunize Bactrian camels, then extracts total RNA from jugular blood lymphocytes, and converts it into cDNA through reverse transcription technology. On this basis, a phage antibody library rich in diversity is constructed by amplifying VHH (nanoantibody) fragments and efficiently connecting them to phagemid vectors. Through three rounds of enrichment screening processes, nanoantibody sequences with high specificity for hemoglobin are successfully isolated from the library, and then through recombinant expression technology, this camel-derived nanoantibody targeting hemoglobin is obtained. In the preparation method proposed by the present invention, only one Bactrian camel needs to be immunized four times to obtain the desired anti-hemoglobin antibody.

[0019] The hemoglobin camel-derived nanoantibody not only has a small molecular weight, but also exhibits excellent stability and strong tissue penetration. It can accurately identify and bind to hidden antigen epitopes that are usually difficult to reach. These characteristics make it have great potential in the field of biomedical research, diagnosis and treatment of clinical diseases, etc. At the same time, the hemoglobin camel-derived nanoantibody proposed in the present invention has the characteristics of high solubility and strong stability, and can also be obtained in large quantities through genetic modification and humanization, and has achieved intracellular drug delivery of intracellular antibodies in clinical practice.

[0020] Through experiments, the EC50 value of the camel-derived hemoglobin nanoantibody of the present invention and hemoglobin is 10.63nM, and its affinity constant KD value is 2.94×10 -7 M, which proves that the hemoglobin camel-derived nanoantibody obtained in the present invention has a better effect and higher affinity, and has a higher sensitivity for hemoglobin recognition.

[0021] Compared with the traditional glycosylated hemoglobin or hemoglobin detection kit, the hemoglobin camel-derived nanoantibody in the kit proposed by the present invention has achieved significant improvement in stability. At the same time, the detection sensitivity and specificity of the kit proposed by the present invention are also improved, providing strong support for the early detection and continuous monitoring of diseases, and optimizing the shortcomings of traditional human monoclonal antibodies such as large molecular weight, low stability, poor tissue penetration, high production cost, and batch differences. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1This is a schematic diagram of the Bactrian camel immunization process in Example 1 of the present invention;

[0023] Figure 2 1 is a data diagram of the P / N values ​​of each orifice plate in Example 1 of the present invention;

[0024] Figure 3 is a schematic diagram of the nucleotide sequence of VHH-12 in Example 1 of the present invention;

[0025] Figure 4 This is a schematic diagram of the purification results of VHH-12-Fc in Example 1 of the present invention;

[0026] Figure 5 Schematic diagram of the experimental results of non-competitive ELISA in Example 2 of the present invention;

[0027] Figure 6 This is a schematic diagram of the BLI experimental results in Example 2 of the present invention;

[0028] Figure 7 Schematic diagram of the results of the VHH-12-Fc specific binding experiment in Example 2 of the present invention. DETAILED DESCRIPTION

[0029] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limitations of the present invention. Those who do not indicate specific techniques or conditions in the embodiments are carried out according to the techniques or conditions described in the literature in this area or according to the product specification. Those who do not indicate the manufacturer of the reagents or instruments used are all conventional products that can be obtained commercially. In the following embodiments, if not clearly stated, "%" refers to weight percentage.

[0030] 1. The Freund's complete adjuvant and Freund's incomplete adjuvant used in the present invention are both commercially available products purchased from Sigma-Aldrich.

[0031] 2. The formula of the antigen diluent solution used in the present invention is 2.43g Tris, 14.61g NaCl dissolved in ultrapure water, the pH is adjusted to 8.0, the volume is made up to 1L, sterilized at 121°C for 20min, and 500mM EDTA is added to a final concentration of 2mM.

[0032] 3. The formula of the solid culture medium used in the present invention is 10g peptone, 5g yeast extract, 10g NaCl, 100mL 20% (w / v) glucose solution is added, ultrapure water is made up to 1L, and sterilized at 121℃ for 20min.

[0033] The preparation method of the hemoglobin camel-derived nanobody in the present invention is as follows:

[0034] S1. Separating hemoglobin antigen from human blood cells to prepare a hemoglobin solution;

[0035] S2, immunizing Bactrian camels four times with hemoglobin solution, with booster immunizations performed at intervals of 20, 60, and 40 days after the initial immunization;

[0036] S3. 15 days after the four immunizations, immune lymphocytes were obtained, and the total RNA of the lymphocytes was extracted to construct a cDNA library, and the cDNA library was then used as a template for specific amplification to obtain nanobody nucleic acid sequences, and the nanobody nucleic acid sequences were used to construct a phage antibody library;

[0037] S4, screening the VHH-12 sequence with hemoglobin specificity through the phage antibody library in step S3;

[0038] S5. Recombinantly express the VHH-12 sequence in step S4 to obtain the hemoglobin camel-derived nanobody.

[0039] Example 1: Preparation method of camel-derived hemoglobin nanobody

[0040] 1. Preparation of hemoglobin solution:

[0041] Hemoglobin is separated and purified from human blood cells, and then the hemoglobin antigen is dissolved in phosphate buffer to obtain a hemoglobin solution.

[0042] 2. Immunization of Bactrian camels:

[0043] The hemoglobin solution prepared in step 1 is mixed with Freund's complete adjuvant in a volume ratio of 1:1 (500 μg of hemoglobin is given to each Bactrian camel for immunization). After complete emulsification, the Bactrian camel is injected subcutaneously, and this injection is regarded as a single immunization. Then, the Bactrian camels are given booster immunizations every 20, 60, and 40 days. Booster immunization refers to mixing the hemoglobin solution with Freund's incomplete adjuvant in a volume ratio of 1:1, and injecting the Bactrian camel intramuscularly after complete emulsification. The single immunization dose is 500 μg of hemoglobin per Bactrian camel. After four immunizations, the immunization of the Bactrian camel is completed. The immunization process is as follows: Figure 1 shown.

[0044] 3. Construction of phage antibody library: 15 days after the last immunization, blood was collected from the jugular vein of Bactrian camels:

[0045] (1) Slowly add the extracted Bactrian camel jugular vein blood into an equal volume of Ficoll separation solution and centrifuge (400g, 25°C, centrifuge for 20 min) to obtain the middle lymphocyte layer. Place the lymphocytes in a centrifuge tube filled with DMEM and centrifuge (500g, centrifuge for 10 min) to collect the cell precipitate. Use an RNA extraction kit to extract total RNA from the cell precipitate and reverse transcribe it into cDNA.

[0046] (2) Using the cDNA obtained in step (1) as a template, the nanosequence was amplified by specific primers, the nucleic acid sequence of the forward primer is shown in SEQ ID NO: 1, and the nucleic acid sequence of the reverse primer is shown in SEQ ID NO: 2. The DNA polymerase used for amplification is the high-fidelity enzyme PrimeSTAR Max DNA Polymerase, and the amplification program is: 98°C, 10s, 57°C, 15s, 72°C, 25s, and 30 cycles. The amplified VHH sequence was recovered using a kit.

[0047] (3) Using pR2 phagemid as a template, specific primers were used to amplify the pR2 phagemid sequence. The nucleic acid sequence of the forward primer for specific primer amplification of pR2 phagemid is shown in SEQ ID NO:3, and the nucleic acid sequence of the reverse primer is shown in SEQ ID NO:4. The DNA polymerase used for amplification was the high-fidelity enzyme PrimeSTAR GXL DNA Polymerase, and the amplification program was: 98°C, 10s, 53°C, 15s, 68°C, 4min 15s, and 30 cycles. The Dpn I enzyme was used to specifically remove the template pR2 phagemid DNA in the amplified product, and then the amplified pR2 phagemid sequence was recovered using a kit.

[0048] (4) Using seamless cloning, the nanobody sequence recovered in step (2) and the pR2 phagemid sequence recovered in step (3) are precisely connected at a molar ratio of 4:1 to obtain a connection product, and the connection product is purified with the aid of a kit. Sterile water is used during the elution process to ensure a sterile environment.

[0049] The obtained ligation product was efficiently transformed by electroporation technology, and the transformed TG1 competent bacteria were cultured in an incubator at 37°C and 200rpm for 1h. 0.2μL and 0.02μL of bacterial solution were evenly spread on 90mm solid culture medium, and the number of colonies was counted after 13 hours of culture, and the total capacity of the constructed antibody library was estimated based on this. The remaining bacterial solution was spread on 5 150mm solid culture media (cultured at 37°C for 13h) after centrifugation, and then the bacterial lawn was scraped, quickly frozen in liquid nitrogen, and stored at -80°C to obtain a phage antibody library.

[0050] 4. Screening of specific camel-derived hemoglobin nanoantibodies:

[0051] (1) The above-mentioned phage antibody library bacteria were activated, and KM13 helper phage was added. After static culture and centrifugation to collect the bacteria, the bacteria were shaken and cultured overnight. Phages were enriched by PEG precipitation method, and the titer of the enriched phages was measured. When the titer of the phage was 1×10 11 When pfu, amplified phage is obtained.

[0052] The wells without hemoglobin coating were used as negative control groups (the negative control group was coated with hemoglobin antigen dilution solution), and the wells coated with hemoglobin solution were used as hemoglobin groups. The hemoglobin group was coated with hemoglobin solution at a concentration of 0.1 mg / mL in a 96-well immunoplate. 11 pfu of amplified phages were incubated at room temperature for 1 hour. Phages that specifically bind to hemoglobin were eluted with trypsin solution, and these phages were used to infect TG1 bacteria. The bacterial liquid infected by phages in the hemoglobin group and the negative control group were taken, diluted and coated on plates, and 50 μL and 5 μL of the diluted bacterial liquid supernatant of the hemoglobin group and the negative control group were taken and coated on solid culture medium for culture, and the number of plaques in the hemoglobin group was greater than that in the negative control group.

[0053] (2) Randomly select 95 single plaques from the solid culture medium in step (1) for activation culture overnight. Add KM13 helper phage to each single plaque to promote phage release, collect the supernatant after lysis by centrifugation, and obtain monoclonal phages respectively.

[0054] The hemoglobin group was coated with hemoglobin at a concentration of 1 μg / mL in the immunoplate, and the above 95 monoclonal phages were added respectively and incubated at room temperature for 1 hour. The phages bound to hemoglobin were captured using HRP-anti M13 antibody, and TMB colorimetric solution was added to each well for 5-10 minutes, and then 1M H2SO4 solution was added to terminate the reaction. The absorbance ratio of each hemoglobin group (P value) to the negative control group (N value) was accurately measured and recorded using an ELISA instrument. The results are shown in Figure 2. Figure 2 As shown. P / N>10 was recorded as a positive plaque, which was used to obtain the hemoglobin-specific antibody sequence.

[0055] (3) Plaques with a P / N value greater than 10 were selected for sequencing analysis. The nucleic acid sequence of the sequencing primer is shown in SEQ ID NO: 5.

[0056] (4) Comparing and analyzing the antibody sequences measured, after eliminating duplicate clones, a specific nanobody sequence VHH-12 was obtained. The nucleotide sequence of VHH-12 is as follows Figure 3 Shown is SEQ ID NO:6.

[0057] 5. Recombinant expression of nano antibody sequences:

[0058] The VHH-12 sequence obtained in step 4 is integrated into the mammalian expression vector pTT5 containing a signal peptide, and the C-terminus is fused with the human IgG1-Fc fragment for expression. By introducing the TEV enzyme cleavage site, the TEV enzyme can be used for precise cleavage when needed, thereby separating the nanobody monomer portion. Subsequently, the recombinant plasmid was successfully transfected into HEK-293F cells, and the cells were cultured and the supernatant was collected. The nanobody Fc fusion protein (VHH-12-Fc) in the supernatant was efficiently purified using rProtein A affinity chromatography technology. VHH-12-Fc is the hemoglobin camel-derived nanobody in the present invention, and its amino acid sequence is shown in SEQ ID NO:7. The purified VHH-12-Fc was sampled and an SDS-PAGE experiment was performed to verify the purity of the obtained antibody, as shown in FIG. Figure 4 As shown, the electrophoresis results showed that the purity of VHH-12-Fc in the obtained sample was high.

[0059] The nucleic acid sequence of the forward primer of the specific primer for amplifying the VHH sequence in the present invention is shown in SEQ ID NO: 1, and the nucleic acid sequence of the reverse primer is shown in SEQ ID NO: 2:

[0060] 5'-GCTGCACAGCCTGCTATGGCACAGKTGCAGCTCGTGGAGTCTGGGGG-3'; SEQ ID NO: 1.

[0061] 5'-GAGTTTTTGTTCGGCTGCTGCTGAGGAGACGGTGACCTGGGTCCCC-3'; SEQ ID NO: 2.

[0062] The nucleic acid sequence of the forward primer for specific amplification of pR2 in the present invention is shown in SEQ ID NO:3, and the nucleic acid sequence of the reverse primer is shown in SEQ ID NO:4:

[0063] 5'-AGCAGCCGAACAAAAACTCATCTCAGAAGAG-3'; SEQ ID NO: 3.

[0064] 5'-CCATAGCAGGCTGTGCAGCATAGAAAGGTACCACTAAAGGAATTGC-3'; SEQ ID NO: 4.

[0065] The nucleic acid sequence of the sequencing primer in the present invention is shown in SEQ ID NO:5:

[0066] 5'-CAGGAAACAGCTATGAC-3'; SEQ ID NO: 5.

[0067] The nucleotide sequence of the camel-derived hemoglobin nanobody of the present invention is shown in SEQ ID NO:6, and the amino acid sequence encoded by it is shown in SEQ ID NO:7.

[0068] CAGTTGCAGCTCGTGGAGTCTGGGGGAGGCCGTGCAGGCAGGGGGGCATCTGAGACTCTCCTGTACAGCCTCTGGATTGGCTTTTGATAATCGTGCCATGGGCTGGTTCCGCCAGGCTCCAGGAAAGGAGCGCGAACCGGTCTCATGTATTAGTACGAGTGGTCGTAGCACATACTATAAAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAACGCCAAAAGCACGCTGTATCTGCAAATGAACAGCCTGAAACCAGAAGACACTGCCGTGTATTACTGTGCGGCCCAGGCCGGAGGTCTGCTGGGTTGGGTACCGAGGTCCTGTCCGCGCGGTCGCTCGTATCTTGGTGCGAAGTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA; SEQ ID NO:6.

[0069] SEQ ID NO:7.

[0070] Example 2: Validation experiment of camel-derived hemoglobin nanobody

[0071] 1. To evaluate the binding properties of VHH-12-Fc to hemoglobin, non-competitive ELISA was used: 5 μg / mL hemoglobin was coated on the immunoplate, 1:5 gradient dilution of VHH-12-Fc was added, and incubated at room temperature for 1 hour. Then, HRP anti-IgG1 Fc antibody was added to detect the bound VHH-12-Fc. The results are as follows: Figure 5 As shown, the EC50 value of VHH-12-Fc and hemoglobin is 10.63 nM.

[0072] 2. In order to further quantify the affinity between the camel-derived hemoglobin nanoantibody (VHH-12-Fc) and hemoglobin in the present invention, the affinity of VHH-12-Fc was characterized by BLI experiment. First, hemoglobin was labeled with biotin to obtain biotinylated hemoglobin (biotin-Hb). Then, it was solidified on the SA biosensor, and different VHH-12-Fc concentration gradients were set to detect the affinity of different VHH-12-Fc concentration gradients with hemoglobin. The results are as follows Figure 6 As shown, the affinity constant KD value of VHH-12-Fc for hemoglobin is 2.94×10 -7 M.

[0073] Typically, the affinity constant KD value of an antibody is around 10 -12 Up to 10 -6 The range of 100 M is considered to have a strong affinity with the target, and the affinity constant KD value of the nanobody is in the sub-nanomolar to low-nanomolar level. This range indicates that the nanobody has a very strong binding ability with the specific antigen and has a high affinity. The affinity constant KD value of the VHH-12-Fc of the present invention for hemoglobin is 2.94×10 -7 M, within the above affinity constant range, indicates that the VHH-12-Fc of the present invention has a high affinity to hemoglobin. This high affinity property makes it have great application potential in the field of drug research and development.

[0074] 3. In order to verify the specificity of VHH-12-Fc, non-competitive ELISA was used to characterize the binding of VHH-12-Fc to hemoglobin and other 8 antigens: 5 μg / mL of hemoglobin (Hb), novel coronavirus receptor binding domain (SARS-CoV-2-RBD), infectious atypical pneumonia receptor binding domain (SARS-RBD), Vibrio parahaemolyticus thermostable direct hemolysin (TDH), ovalbumin (OVA), bovine serum albumin (BSA), green fluorescent protein (GFP), matrix metalloproteinase-1 (collagenase) (MMP-1) and polyphenoloxidase (Polyphenoloxidase, PPO) were coated in the immunoplate. Add 1:5 gradient dilution of VHH-12-Fc, incubate at room temperature for 1 hour, and then add HRP anti-IgG1 Fc antibody to detect the bound VHH-Fc. The results are as follows. Figure 7 As shown, the experimental results showed that the hemoglobin camel-derived nanoantibody only specifically binds to hemoglobin and does not show any cross-reaction with the other eight antigens, thereby confirming its high antigen specificity.

[0075] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and purpose of the present invention.

Claims

1. A hemoglobin camel-derived nanobody, characterized in that: The amino acid sequence of the hemoglobin camel-derived nanobody is shown in SEQ ID NO:

7.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule is used to encode the hemoglobin camel-derived nanobody according to claim 1, and the nucleic acid molecule is the nucleic acid sequence shown in SEQ ID NO:

6.

3. A method for preparing a hemoglobin camel-derived nanobody, characterized in that: For preparing the hemoglobin camel-derived nanobody described in claim 1, comprising: S1. Separating hemoglobin antigen from human blood cells to prepare a hemoglobin solution; S2, immunizing Bactrian camels four times with hemoglobin solution, with booster immunizations performed at intervals of 20, 60, and 40 days after the initial immunization; S3. 15 days after the four immunizations, immune lymphocytes were obtained, and the total RNA of the lymphocytes was extracted to construct a cDNA library, and the cDNA library was then used as a template for specific amplification to obtain nanobody nucleic acid sequences, and the nanobody nucleic acid sequences were used to construct a phage antibody library; S4, screening the VHH-12 sequence with hemoglobin specificity through the phage antibody library in step S3; S5. Recombinantly express the VHH-12 sequence in step S4 to obtain the hemoglobin camel-derived nanobody.

4. A phage antibody library, characterized in that: The phage antibody library obtained by the preparation method of claim 3 comprises the nucleic acid sequence of SEQ ID NO: 6 described in claim 2.

5. A detection kit, characterized in that: It includes the camel-derived hemoglobin nanobody as described in claim 1 or the camel-derived hemoglobin nanobody obtained by the preparation method as described in claim 3.

Citation Information

Patent Citations

  • Natural nanometer antibody library for Bactrian camel phage display as well as construction method and usage thereof

    CN104404630A

  • Serum ferritin specific nano antibody and ELISA (enzyme-linked immuno sorbent assay) method thereof

    CN114656557A

  • Anti-HbA1c nano antibody as well as preparation method and application thereof

    CN116217720A

  • Hemoglobin shark source nano antibody as well as preparation method and application thereof

    CN117567609A

  • Camelid hemoglobin antibodies and methods of use

    US20190023806A1